CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection.
暂无分享,去创建一个
R. Mitchell | P. Ganz | D. Briscoe | C. Geehan | M. Denton | R. Reul | C. Long | J. Fang | Ross M. Reul | R. Mitchell | Christopher S. Geehan
[1] T. Nishi,et al. Analysis of initial attachment of B cells to endothelial cells under flow conditions. , 1997, Journal of immunology.
[2] J. Banchereau,et al. CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation. , 1997, Journal of immunology.
[3] R. Flavell,et al. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. , 1997, Journal of immunology.
[4] E. Clark,et al. Functional CD40 ligand expressed by human blood dendritic cells is up-regulated by CD40 ligation. , 1996, Journal of immunology.
[5] R. Flavell,et al. A central role of CD40 ligand in the regulation of CD4+ T-cell responses. , 1996, Immunology today.
[6] R. Armitage,et al. Repression of apoptosis in human B-lymphoma cells by CD40-ligand and Bcl-2: relationship to the cell-cycle and role of the retinoblastoma protein. , 1996, Oncogene.
[7] M. Urashima,et al. CD40 ligand triggers interleukin-6 mediated B cell differentiation. , 1996, Leukemia research.
[8] P. Linsley,et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways , 1996, Nature.
[9] C. Orosz,et al. Can graft endothelial cells initiate a host anti-graft immune response? , 1996, Transplantation.
[10] A. Aruffo,et al. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. , 1996, Transplantation.
[11] D. Gray,et al. CD40 ligand-transduced co-stimulation of T cells in the development of helper function , 1995, Nature.
[12] L. Chess,et al. Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals , 1995, The Journal of experimental medicine.
[13] S. Fortune,et al. Ligation of CD40 on fibroblasts induces CD54 (ICAM‐1) and CD106 (VCAM‐1) up‐regulation and IL‐6 production and proliferation , 1995, Journal of leukocyte biology.
[14] P. Kiener,et al. Expression of functional CD40 by vascular endothelial cells , 1995, The Journal of experimental medicine.
[15] R. Kroczek,et al. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation , 1995, European journal of immunology.
[16] L. Davis,et al. The CD40 ligand expressed by human B cells costimulates B cell responses. , 1995, Journal of immunology.
[17] P. Linsley,et al. Studies on the interdependence of gp39 and B7 expression and function during antigen‐specific immune responses , 1995, European journal of immunology.
[18] A. Yeung,et al. Prdictive Value Of Inducible Endothelial Cell Adhesion Molecule Expression For Acte Rejection Of Human Cardiac Allografts , 1995, Transplantation.
[19] R J Armitage,et al. Humoral immune responses in CD40 ligand-deficient mice , 1994, The Journal of experimental medicine.
[20] M. Jenkins. The ups and downs of T cell costimulation. , 1994, Immunity.
[21] A. Aruffo,et al. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. , 1994, The Journal of clinical investigation.
[22] R. Flavell,et al. Mice deficient for the CD40 ligand. , 1994, Immunity.
[23] H. Ochs,et al. Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction. , 1994, Journal of immunology.
[24] N. Yoshida,et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. , 1994, Immunity.
[25] F. Ramsdell,et al. Recombinant CD40 ligand exerts potent biologic effects on T cells. , 1994, Journal of immunology.
[26] H. Ochs,et al. B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells , 1993, The Journal of experimental medicine.
[27] F. Ramsdell,et al. CD40 ligand is a T cell growth factor , 1993, European journal of immunology.
[28] A. Aruffo,et al. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. , 1993, Journal of immunology.
[29] W. Fanslow,et al. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40 , 1993, The Journal of experimental medicine.
[30] W. Fanslow,et al. Human B cell proliferation and Ig secretion induced by recombinant CD40 ligand are modulated by soluble cytokines. , 1993, Journal of immunology.
[31] L. Notarangelo,et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM , 1993, Nature.
[32] C. Maliszewski,et al. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion , 1992, The Journal of experimental medicine.
[33] H. Mages,et al. Cloning of TRAP, a ligand for CD40 on human T cells , 1992, European journal of immunology.
[34] I. Stamenkovic,et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co‐stimulatory activity. , 1992, The EMBO journal.
[35] P. Linsley,et al. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. , 1992, Journal of immunology.
[36] G. Rice,et al. Inducible cell adhesion molecule 110 (INCAM-110) is an endothelial receptor for lymphocytes. A CD11/CD18-independent adhesion mechanism , 1990, The Journal of experimental medicine.
[37] G. Freeman,et al. Isolated human follicular dendritic cells display a unique antigenic phenotype , 1989, The Journal of experimental medicine.
[38] L. Young,et al. Identification of a human epithelial cell surface protein sharing an epitope with the C3d/epstein‐barr virus receptor molecule of B lymphocytes , 1989, International journal of cancer.
[39] Michael Loran Dustin,et al. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. , 1986, Journal of immunology.